A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26774
- Registration Number
- NCT03993132
- Locations
- 🇩🇰
Department of Clinical Epidemiology - Aarhus Unversiteteshospital, Aarhus, Denmark
This Study Observes the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) in Elderly Patients With a Heart Rhythm Disorder in Spain
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: Non-vitamin K antagonist oral anticoagulant
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 500
- Registration Number
- NCT03993119
- Locations
- 🇪🇸
H. de Mataró, Mataró, Barcelona, Spain
🇪🇸H. Fundación Alcorcón, Alcorcón, Madrid, Spain
🇪🇸Consulta Privada, Valencia, Spain
A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03988803
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Olodaterol/Tiotropium BromideDrug: Umeclidinium/ Vilanterol
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 11296
- Registration Number
- NCT03979807
- Locations
- 🇺🇸
Aetion Inc., New York, New York, United States
A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT03979820
- Locations
- 🇳🇱
PRA Health Sciences Onderzoekscentrum Martini, Groningen, Netherlands
Evaluation of Safety and Tolerability of BI 894416 in Patients With Mild Asthma
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: BI 894416Drug: Placebo
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 68
- Registration Number
- NCT03971539
- Locations
- 🇩🇪
Fraunhofer ITEM, Hannover, Germany
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: BI 836880Drug: BI 754091
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21
- Registration Number
- NCT03972150
- Locations
- 🇯🇵
Shizuoka Cancer Center, Shizuoka, Sunto-gun, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Chuo-ku, Japan
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 706321Drug: Placebo
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 61
- Registration Number
- NCT03971695
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT03964207
- Locations
- 🇨🇳
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, China
🇨🇳The First Hospital of China Medical University, Shenyang, China
Impact of Tiotropium Add-on Therapy in Patients With Asthma
Completed
- Conditions
- Asthma
- Interventions
- Drug: Tiotropium Respimat®Drug: Inhaled Corticosteroid/Long-acting beta-agonist
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7857
- Registration Number
- NCT03964220
- Locations
- 🇺🇸
eMax Health, White Plains, New York, United States
© Copyright 2025. All Rights Reserved by MedPath